A Popular Anti-Aging Drug Combo May Come at a Cost to the Brain

Key takeaways

• A drug combination often studied for longevity (dasatinib + quercetin) caused significant myelin loss in mice.
• Myelin, which helps nerve signals travel efficiently, was reduced in both young and older animals.
• Instead of dying, myelin-producing cells regressed into a less mature, less functional state.
• The treatment also disrupted cellular energy metabolism, which may underlie these changes.
• Findings are preclinical, but highlight the importance of carefully evaluating the brain effects of longevity compounds.

As interest in longevity interventions grows, so does the need to understand their full-body effects—especially in the brain. A new study from the University of Connecticut raises important questions about one of the most widely discussed drug combinations in aging research.

The pairing of dasatinib and quercetin (often referred to as D+Q) has been studied for its ability to clear senescent cells—older cells that accumulate over time and contribute to inflammation. But in this study, researchers found that the same combination may have unintended effects on the brain’s structural integrity.

A closer look at myelin

Myelin is a fatty, protective layer that wraps around nerve fibers, helping electrical signals move quickly and efficiently. It plays a central role in coordination, cognition, and communication between different parts of the brain.

In healthy mice, myelin forms thick, continuous sheaths along neurons. But after treatment with D+Q, researchers observed a striking reduction in this protective coating.

• Myelin layers became thinner or disappeared altogether

• Structural integrity in key brain regions declined

• Younger mice showed even greater sensitivity to these changes

This suggests that the effects were not limited to already aged systems.

Cells that lose function—but don’t disappear

One of the more unexpected findings was what happened to oligodendrocytes—the cells responsible for producing myelin.

Rather than dying off, many of these cells appeared to revert to a more immature state. They lost their specialized structure and function, becoming less capable of maintaining myelin.

This kind of regression points to a shift in cellular identity, rather than simple cell loss.

A possible role for cellular energy

The researchers also identified disruptions in how these cells manage energy.

Oligodendrocytes are metabolically active, requiring substantial energy to produce and maintain myelin. The drug combination appeared to interfere with this process, potentially “choking off” the energy supply needed to sustain normal function.

In response, cells may simplify—reducing their complexity and reverting to a state that requires less energy, but also provides less support to neural networks.

What this means for longevity research

D+Q remains an area of active investigation, particularly for its potential to influence aging-related processes. However, this study underscores a broader point: interventions that affect one aspect of biology may have unintended consequences elsewhere.

From a systems perspective, the brain is especially sensitive to shifts in:

• Structural support (like myelin)

• Cellular identity and specialization

• Energy availability and metabolism

Even subtle disruptions in these areas can influence how neural networks function over time.

What this does and doesn’t show

These findings come from animal models and lab-grown cells, and human responses may differ. The study also focuses on a specific dosing context, which may not reflect all real-world scenarios.

Importantly, it does not negate the potential value of senolytic approaches, but it does highlight the need for a more nuanced understanding of tissue-specific effects.

As longevity science advances, this kind of work helps refine the bigger picture: optimizing aging may depend not just on removing what’s dysfunctional, but on preserving the systems that keep complex tissues—like the brain—running smoothly.

References:

1. Evan R. Lombardo, Robert S. Pijewski, Jake T. Lustig, Zaenab Dhari, Anirudhya Lahiri, Lucille E. Papile, Erica R. Lavoie, Vanessa M. Scanlon, Jenna M. Bartley, Stephen J. Crocker. Senolytic treatment induces oligodendrocyte dysfunction and demyelination in the corpus callosum. Proceedings of the National Academy of Sciences, 2026; 123 (12) DOI: 10.1073/pnas.2524897123